DNER: A Potential Drug Target and Biomarker (G92737)

Target Name: DNER

NCBI ID: G92737

DNER

DNER: A Potential Drug Target and Biomarker

DNER (delta/notch-like EGF repeat containing) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. DNER is a highly conserved gene that is found in various organisms, including humans. It is characterized by the presence of a double-stranded RNA structure and the conserved EGF repeat. The EGF repeat is a transmembrane domain that is known for its ability to interact with various signaling molecules, including TGF-β1.

DNER function

DNER is involved in various cellular processes, including cell growth, differentiation, and survival. It has been shown to play a role in the regulation of cell proliferation and survival. DNER has been shown to be involved in the regulation of cell cycle progression, and it has been shown to play a role in the regulation of apoptosis.

DNER has also been shown to be involved in the regulation of cell adhesion. DNER has been shown to interact with various signaling molecules, including EGFR, which is a transmembrane receptor that is involved in the regulation of cell growth and survival. This interaction between DNER and EGFR suggests that DNER may be a potential drug target for the treatment of various diseases, including cancer.

DNER as a biomarker

DNER has also been shown to be a potential biomarker for various diseases. For example, DNER has been shown to be elevated in various types of cancer, including breast cancer, lung cancer, and colon cancer. This suggests that DNER may be a potential biomarker for the diagnosis and prognosis of these diseases.

DNER has also been shown to be elevated in various types of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. This suggests that DNER may be a potential biomarker for the diagnosis and treatment of these diseases.

DNER as a drug target

Given its involvement in various cellular processes and its potential as a biomarker, DNER is a promising drug target. The use of small molecules, such as drugs that bind to specific interacting proteins, may be an effective way to target DNER and modulate its function.

One potential approach to targeting DNER is the use of small molecules that bind to the EGF repeat. This approach is based on the idea that the conserved EGF repeat in DNER may be a target for small molecules that can modulate its function.

In conclusion

DNER is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. Its conserved EGF repeat and its involvement in various cellular processes make it a promising target for small molecules that can modulate its function. Further research is needed to fully understand the role of DNER in cellular processes and its potential as a drug target and biomarker.

Protein Name: Delta/notch Like EGF Repeat Containing

Functions: Activator of the NOTCH1 pathway. May mediate neuron-glia interaction during astrocytogenesis (By similarity)

The "DNER Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DNER comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets